Brucellosis (Undulant Fever)

1. Comprehensive Introduction & Overview

Brucellosis, historically referred to as Undulant Fever, Malta Fever, or Mediterranean Fever, is a quintessential zoonotic infection caused by bacteria of the genus Brucella. It remains one of the most widespread zoonoses globally, posing a significant challenge to public health, particularly in endemic regions including the Mediterranean basin, the Middle East, parts of Asia, and Latin America.

The disease is characterized by a multisystemic involvement, often manifesting as an acute febrile illness that can progress to a chronic, debilitating state if left untreated. Its clinical hallmark—the "undulant" fever—refers to a pattern of recurring waves of pyrexia, though modern clinical presentations are highly variable. As an expert clinician, it is vital to recognize that Brucellosis is a systemic mimic; it can masquerade as almost any infectious or inflammatory condition, making a high index of clinical suspicion the primary diagnostic tool in the initial encounter.

Epidemiological Context

The transmission of Brucella to humans is primarily through the ingestion of unpasteurized dairy products, direct contact with infected animal tissues (typically livestock such as goats, sheep, cattle, and swine), or inhalation of aerosolized bacteria in laboratory or slaughterhouse settings.

2. Deep-Dive: Etiology and Pathophysiology

The Pathogen: Brucella Species

Brucella are small, non-motile, non-spore-forming, Gram-negative coccobacilli. They are facultative intracellular pathogens that possess a unique ability to survive and replicate within the host’s mononuclear phagocyte system (MPS).

Mechanisms of Infection

1. Entry: The bacteria enter the host via the gastrointestinal tract, respiratory mucosa, or skin abrasions.
2. Cellular Invasion: Once in the bloodstream, Brucella are phagocytosed by macrophages and neutrophils.
3. Intracellular Survival: Unlike many bacteria that are destroyed within the phagolysosome, Brucella inhibits phagosome-lysosome fusion and creates a protected niche within the endoplasmic reticulum.
4. Dissemination: The bacteria reside primarily in the spleen, liver, bone marrow, and lymph nodes. The formation of granulomas is a hallmark of the body’s attempt to contain the infection, often leading to the clinical manifestations of focal disease (e.g., osteomyelitis, orchitis, endocarditis).

3. Clinical Indications & Standard Presentation

Brucellosis is clinically categorized into three phases: acute, subacute, and chronic. However, clinical presentation is often nonspecific, complicating early diagnosis.

Clinical Staging

• Acute Phase: Onset can be abrupt or insidious. Symptoms typically include high-grade, intermittent fever (undulant pattern), profuse nocturnal sweating, arthralgia, myalgia, and profound malaise.
• Subacute Phase: Characterized by localized infection. Common sites include the sacroiliac joints (sacroiliitis), spine (spondylitis), and reproductive organs (orchitis/epididymitis).
• Chronic Phase: Defined as symptoms persisting beyond 12 months. This phase is often associated with localized focal infection, depression, chronic fatigue, and joint destruction.

Diagnostic Matrix: Clinical Findings

4. Differential Diagnosis

Because Brucellosis is a "great imitator," the differential diagnosis is vast. Clinicians must rule out:
* Tuberculosis: Often presents with chronic fever, night sweats, and localized bone involvement.
* Typhoid Fever: Similar febrile pattern and gastrointestinal involvement.
* Malaria: Important in travel history; causes periodic fever.
* Rheumatological Conditions: SLE or Rheumatoid Arthritis, especially when joint pain is the presenting symptom.
* Lymphoma: Given the common presentation of fever, weight loss, and lymphadenopathy.

5. Key Diagnostic Tests

A diagnosis of Brucellosis requires a combination of epidemiological history, clinical findings, and laboratory confirmation.

Laboratory Gold Standards

1. Blood Culture: The gold standard, although sensitivity can be low (especially in chronic cases). Automated systems (BACTEC) have improved detection rates.
2. Serology:
   • Serum Agglutination Test (SAT): Measures IgM and IgG. A titer of ≥1:160 is generally considered diagnostic in endemic areas.
   • 2-Mercaptoethanol (2-ME) Test: Used to differentiate IgM (acute) from IgG (chronic/past infection).
3. Molecular Diagnostics: PCR-based assays are highly sensitive and specific, proving particularly useful in detecting Brucella DNA in synovial fluid, abscesses, or blood.
4. Imaging: MRI is essential for identifying focal complications, particularly in cases of suspected spondylitis or sacroiliitis.

6. Risks, Side Effects, and Contraindications

Treating Brucellosis requires prolonged, multi-drug therapy to prevent relapse, as the intracellular nature of the pathogen makes it resistant to monotherapy.

Standard Therapeutic Regimen

• Adults: Doxycycline (100mg BID) combined with Rifampin (600-900mg daily) for at least 6 weeks.
• Alternative: Doxycycline plus Streptomycin or Gentamicin for more severe or focal cases.

Risks and Contraindications

• Doxycycline: Contraindicated in pregnancy (Category D) and children under 8 years of age due to tooth discoloration and enamel hypoplasia.
• Rifampin: Known for significant drug-drug interactions (CYP450 inducer). Patients on anticoagulants or birth control must be counseled.
• Streptomycin/Gentamicin: Nephrotoxicity and ototoxicity are primary concerns; renal function must be monitored.

7. Long-Term Prognosis

The prognosis for Brucellosis is generally favorable with prompt and compliant antibiotic therapy. However, the relapse rate can be as high as 10-20% if the treatment duration is insufficient. Chronic Brucellosis, characterized by persistent focal disease, may require surgical intervention (e.g., debridement of infected bone, valve replacement in endocarditis) alongside prolonged antibiotic suppression.

8. Massive FAQ Section

1. Is Brucellosis contagious between humans?
Human-to-human transmission is extremely rare. It can occur via breastfeeding, blood transfusions, or bone marrow transplants, but person-to-person spread via respiratory droplets is not a recognized risk.

2. Can I get Brucellosis from pasteurized milk?
No. Proper pasteurization of dairy products is the most effective public health measure for preventing Brucellosis.

3. Why is the fever called "undulant"?
The term refers to the classic pattern where the fever rises and falls in a wave-like (undulating) manner, often occurring over weeks or months. However, many modern patients present with constant or irregular fevers.

4. What is the most common joint affected in Brucellosis?
The sacroiliac joint is the most frequently affected joint, often presenting as unilateral or bilateral sacroiliitis.

5. How long does treatment last?
Treatment is typically extended. For uncomplicated cases, a minimum of 6 weeks is standard. Focal disease (e.g., spondylitis) may require 3–6 months of combination therapy.

6. Can Brucellosis be cured completely?
Yes, if caught early and treated with the correct multi-drug regimen. If the infection has progressed to chronic tissue damage (e.g., joint destruction), the infection may be cleared, but the sequelae may persist.

7. Is there a vaccine for humans?
Currently, there is no FDA-approved vaccine for humans. Veterinary vaccines exist but are not used in humans due to their own pathogenic potential.

8. What should I do if I suspect I have been exposed?
Seek medical attention immediately. Do not wait for symptoms to appear. Inform your physician about the specific nature of the exposure (e.g., consumption of raw goat cheese, laboratory exposure).

9. Does Brucellosis affect pregnancy?
Yes. Brucellosis during pregnancy is associated with an increased risk of spontaneous abortion, intrauterine fetal death, and premature delivery. Treatment in pregnancy is complex and requires specialized infectious disease management.

10. Can Brucellosis cause long-term fatigue?
Yes, chronic fatigue syndrome-like symptoms are frequently reported in patients who have recovered from the acute phase of the infection, often referred to as "Chronic Brucellosis Syndrome."

9. Conclusion for the Specialist

As an orthopedic or clinical specialist, your role in managing Brucellosis is to maintain a high index of clinical suspicion for patients presenting with "fever of unknown origin" combined with musculoskeletal pain. The combination of prolonged antibiotic therapy and, where necessary, surgical debridement, remains the cornerstone of management. Always prioritize the prevention of relapse by ensuring strict adherence to the multi-drug antibiotic regimen. In the context of global travel and the consumption of artisanal or unpasteurized dairy products, Brucellosis remains a relevant and critical diagnosis in modern clinical practice.